Treats idiopathic pulmonary fibrosis. Sold as Jascayd. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 2 applications for Nerandomilast (sold as Jascayd), first approved Oct 7, 2025, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 7, 2025 | JascaydNDA 218764 · New molecular entity | Boehringer Ingelheim | 2 | Marketed |
| Dec 19, 2025 | JascaydNDA 220449 · New indication | Boehringer Ingelheim | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Boehringer Ingelheim